$5.24
-0.52 (-9.03%)
Open$5.63
Previous Close$5.76
Day High$5.67
Day Low$5.17
52W High$23.43
52W Low$2.90
Volume—
Avg Volume122.4K
Market Cap36.03M
P/E Ratio—
EPS$-2.65
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+124.6% upside
Current
$5.24
$5.24
Target
$11.77
$11.77
$8.46
$11.77 avg
$14.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.52M | 35.79M | 31.57M |
| Net Income | -49,452,756 | 827.5K | 932.2K |
| Profit Margin | -429.4% | 2.3% | 3.0% |
| EBITDA | -34,941,435 | 1.82M | 1.58M |
| Free Cash Flow | — | 629.7K | 483.5K |
| Rev Growth | +187.2% | +6.8% | +6.0% |
| Debt/Equity | 0.19 | 0.61 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |